Journal profile · Medicine-Oncology
Trends in Cancer
ISSN 2405-8025 · Elsevier · United States
Trends in Cancer: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 21.39; hybrid open access; APC about USD 7,030; median 92 days to acceptance (92 articles, last 24 months); 142 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Trends in Cancer is published by Elsevier and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Cancer Genomics and Diagnostics and Cancer Immunotherapy and Biomarkers, together about 28.3% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Trends in Cancer is a new member of the Trends review journals, offering concise and engaging expert commentary articles that address key frontline research topics and cutting-edge advances in the rapidly changing field of cancer discovery and medicine. The journal provides a unique platform for multidisciplinary information, discussion and education that is valuable for scientists, clinicians, and policy makers, as well as patients and advocates. The latest opportunities, challenges and potential impact of basic, translational and clinical findings, industry R&D, technology and innovation, ethics, or cancer policy and funding are equally presented and debated in an authoritative but reader-friendly format.Critical issues to be covered in the journal include: Adult and Pediatric Cancers; Personalized Medicine; Tumor Microenvironment, Resistance and Metastasis; Immunotherapy; Metabolism; Genetics and Epigenetics; Diagnostics, Biomarkers and Treatment; Epidemiology and Cancer Prevention; Cancer related Ethics, Policy and Funding Initiatives.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance10.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology9.3%
- Cancer Immunotherapy and BiomarkersMedicine8.2%
- Legal Cases and CommentaryMedicine7.2%
- Cancer Cells and MetastasisMedicine5.8%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology5.1%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5%
- CAR-T cell therapy researchMedicine4.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 21.39LetPub ·
- Impact factor (publisher)
- 21.6Publisher website ·
- CiteScore 2026-06
- 30.8LetPub ·
- CiteScore (publisher)
- 30.8Publisher website ·
- SJR 2026-06
- 5.49LetPub ·
- SNIP 2026-06
- 3.26LetPub ·
- h-index
- 141OpenAlex ·
- i10-index
- 817OpenAlex ·
- 2-year mean citedness
- 11OpenAlex ·
- Self-citation rate
- 0.9%LetPub ·
- Share of gold OA articles
- 29.52%LetPub ·
Volume
- Articles per year
- 72LetPub ·
Articles by year OpenAlex count · 1,422 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 110 | 42 | 79 |
| 2025 | 142 | 65 | 1,140 |
| 2024 | 134 | 78 | 3,028 |
| 2023 | 136 | 80 | 5,137 |
| 2022 | 130 | 81 | 5,811 |
| 2021 | 125 | 74 | 6,176 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
92 daysMedian, submission to acceptance · P25–P75 60 days – 132 days
- Acceptance to online
- median 24 days (92 articles)
- Submission to online
- median 121 days
- Sample
- 92 articles with submission and acceptance dates (246 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 2 daysPublisher website ·
- Submission to acceptance
- 54 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,030 / EUR 6,510 / GBP 5,630 / JPY 871,930 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- United States
- Language
- English
- ISSN
- 2405-8025
- Print ISSN
- 2405-8033
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Trends in Cancer
What CAS zone is Trends in Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Trends in Cancer is in Zone 1 of Medicine, and in Zone 2 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Trends in Cancer?
The latest impact factor listed by LetPub is 21.39; CiteScore 30.8, h-index 141.
How long does peer review take at Trends in Cancer?
Based on the dates recorded on 92 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 60–132 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Trends in Cancer?
According to LetPub and DOAJ records, Trends in Cancer is indexed in SCIE and Scopus.
Is Trends in Cancer open access, and what is the APC?
Trends in Cancer is a hybrid journal. For open-access publication: APC about USD 7,030.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .